Home > Urology > ASCO GU 2021 > Urothelial Cancer > Signature DNA alterations in subtypes of bladder cancer

Signature DNA alterations in subtypes of bladder cancer

Presented By
Dr Andrew Thomas Lenis, Memorial Sloan Kettering Cancer Centre, New York, USA
Conference
ASCO GU 2021
Attempts to identify a signature DNA alteration pathognomonic of differing histologic subtypes of bladder cancer have been unsuccessful to date. Urothelial carcinomas encompass a vast array of histological morphologies, some of which are more aggressive than others. For this reason, the histomorphologic features of bladder cancer carry a prognostic significance, and different variants necessitate different treatment approaches. Dr Andrew Thomas Lenis (Memorial Sloan Kettering Cancer Centre, New York, USA) shared results from his team’s genomic sequencing of bladder cancers of varying histologies in an attempt to determine whether these urothelial cancer variants had pathognomonic genomic profiles [1]. Memorial Sloan Kettering Cancer Centre developed the MSK-IMPACT™ test (authorised by the FDA in 2017) to analyse tumours for >400 mutations known to play a role in cancer. They used this test to identify gene alterations across a prospectively gener...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on